The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.c

Exacerbation or deterioration of preexisting asthma

Publications

Marcus K, Lee DJ, Wilson JS, Smith RJH, Puricelli M

Pembrolizumab Induced Acute Persistent Airway Disease in a Patient with Recurrent Respiratory Papillomatosis (RRP).

The Annals of otology, rhinology, and laryngology 2021 May 30;;34894211021276 — 2021 May 30 — 34894211021276

Ogawa T, Miyata J, Maehara J, Inoue T, Betsuyaku T

Fatal Airway Inflammation Induced by Pembrolizumab in a Patient With NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Jan;14;e9-e10 — 2019 Jan — e9-e10